



## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology – Scemblix Prior Authorization Policy

- Scemblix® (asciminib tablets – Novartis)

**REVIEW DATE:** 03/25/2026

### INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

## CIGNA NATIONAL FORMULARY COVERAGE:

### OVERVIEW

Scemblix, a kinase inhibitor, is indicated for the following uses:<sup>1</sup>

- **Chronic myeloid leukemia (CML)**, Philadelphia chromosome positive (Ph+), chronic phase, in newly diagnosed adults.
- **CML**, Ph+, chronic phase, in previously treated adults.
- **CML**, Ph+, chronic phase with the T315I mutation in adults.

The indication in newly diagnosed patients is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial.

### Guidelines

Scemblix is discussed in guidelines from National Comprehensive Cancer Network (NCCN):

- **Acute Lymphoblastic Leukemia (ALL):** NCCN guidelines (version 2.2025 – June 27, 2025) recommend Scemblix + dasatinib for relapsed or refractory Ph+ B-ALL.<sup>2</sup>
- **CML:** NCCN guidelines (version 1.2026 – July 16, 2025) recommend Scemblix for patients with newly diagnosed chronic phase Ph+ or BCR::ABL1-positive CML with a

low risk, intermediate-risk, or high-risk score as a “Preferred” primary treatment (category 1).<sup>3</sup> Scemblix is recommended as “Useful in Certain Circumstances” (category 2A) for accelerated phase CML (category 2A). Scemblix is a treatment option for chronic phase CML (Ph+ or *BCR-ABL1*-positive) in patients with the T315I mutation and/or previously treated chronic phase CML or accelerated phase CML (category 2A).

- **Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions:** NCCN guidelines (version 1.2026 – October 3, 2025) recommend Scemblix as “Other Recommended Regimens” for *ABL1* rearrangements in chronic phase or blast phase (category 2A).<sup>4</sup> It is also recommended as treatment in combination with ALL or acute myeloid leukemia-type induction chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT) [if eligible] for lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia and *ABL1* rearrangement in blast phase (category 2A).

#### **POLICY STATEMENT**

Prior Authorization is recommended for prescription benefit coverage of Scemblix. All approvals are provided for the duration noted below.

- **Scemblix® (asciminib tablets ( Novartis))**

**is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

#### **FDA-Approved Indication**

- 1. Chronic Myeloid Leukemia.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):
  - A)** Patient is  $\geq 18$  years of age; AND
  - B)** Patient meets ONE of the following (i or ii):
    - i. Patient has Philadelphia chromosome-positive chronic myeloid leukemia; OR
    - ii. Patient has *BCR::ABL1*-positive chronic myeloid leukemia; AND
  - C)** Patient meets ONE of the following (i, ii, or iii):
    - i. Patient has newly diagnosed disease; OR
    - ii. The chronic myeloid leukemia is T315I-positive; OR
    - iii. Patient has tried at least one other tyrosine kinase inhibitor.  
Note: Examples of tyrosine kinase inhibitors include imatinib, Bosulif (bosutinib tablets and capsules), Iclusig (ponatinib tablets), dasatinib, Danziten (nilotinib tablets), Tasigna (nilotinib capsules), and Nilotinib capsules.

#### **Other Uses with Supportive Evidence**

- 2. Acute Lymphoblastic Leukemia.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):
  - A)** Patient is  $\geq 18$  years of age; AND
  - B)** Patient has Philadelphia chromosome-positive acute lymphoblastic leukemia; AND
  - C)** The medication will be used in combination with dasatinib.
- 3. Myeloid/Lymphoid Neoplasms with Eosinophilia.** Approve for 1 year if the patient meets BOTH of the following (A and B):
  - A)** Patient is  $\geq 18$  years of age; AND
  - B)** The tumor has an *ABL1* rearrangement.

## CONDITIONS NOT COVERED

- **Scemblix® (asciminib tablets ( Novartis)**

**is(are) considered not medically necessary for ANY other use(s).**

### REFERENCES

1. Scemblix® tablets [prescribing information]. East Hanover, NJ: Novartis; November 2025.
2. The NCCN Acute Lymphoblastic Leukemia Clinical Practice Guidelines in Oncology (version 2.2025 – June 27, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on March 20, 2026.
3. The NCCN Chronic Myeloid Leukemia Clinical Practice Guidelines in Oncology (version 1.2026 – July 16, 2025) © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on March 20, 2026.
4. The NCCN Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Clinical Practice Guidelines in Oncology (version 1.2026 – October 3, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on March 20, 2026.

### HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	05/01/2024
Selected Revision	<b>Chronic Myeloid Leukemia:</b> Added new criteria to approve for use in patients with newly diagnosed disease based on FDA approval.	11/13/2024
Selected Revision	<b>Chronic Myeloid Leukemia:</b> The criterion of trial at least two other tyrosine kinase inhibitors indicated for use in Philadelphia chromosome-positive chronic myeloid leukemia was changed to "at least one" other tyrosine kinase inhibitor indicated for use in Philadelphia chromosome-positive chronic myeloid leukemia based on updated labeling and NCCN guideline recommendations.	12/11/2024
Annual Revision	<b>Chronic Myeloid Leukemia:</b> The following option for approval was added, "patient has <i>BCR::ABL1</i> -positive chronic myeloid leukemia." The following wording "...indicated for use in Philadelphia chromosome positive chronic myeloid leukemia" was removed from the requirement of trial of at least one other tyrosine kinase inhibitor. Danziten (nilotinib tablets) and Nilotinib capsules were added to the note of examples of tyrosine kinase inhibitors and the brand name Sprycel was removed.	03/26/2025
Selected Revision	<b>Acute Lymphoblastic Leukemia:</b> Condition of approval and criteria were added to "Other Uses with Supportive Evidence."	09/10/2025
Annual Revision	No criteria changes.	03/25/2026

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company,

Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2026 The Cigna Group.